We wouldn't blame Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shareholders if they were a little worried about the fact that Bartholomew Canton, the Founder recently netted about US$1.1m selling shares at an average price of US$3.12. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 1.3%.

View our latest analysis for Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Insider Transactions Over The Last Year

Notably, that recent sale by Bartholomew Canton is the biggest insider sale of Ginkgo Bioworks Holdings shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$3.09. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

Insiders in Ginkgo Bioworks Holdings didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

I will like Ginkgo Bioworks Holdings better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Insider Ownership Of Ginkgo Bioworks Holdings

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Ginkgo Bioworks Holdings insiders own 29% of the company, worth about US$1.6b. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Ginkgo Bioworks Holdings Insider Transactions Indicate?

Insiders haven't bought Ginkgo Bioworks Holdings stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Ginkgo Bioworks Holdings. In terms of investment risks, we've identified 3 warning signs with Ginkgo Bioworks Holdings and understanding these should be part of your investment process.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.